FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
● Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic...
Source: Roche Media News - April 13, 2021 Category: Pharmaceuticals Source Type: news
Arthritis Drug May Curb Myocardial Damage in Acute STEMI Arthritis Drug May Curb Myocardial Damage in Acute STEMI
Tocilizumab appears to improve myocardial salvage by helping tamp down the inflammatory overshoot that occurs during infarction and reperfusion.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 13, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
Providing patient information leaflets following COVID-19 treatment, SPS
Following treatment for COVID-19 with tocilizumab, sarilumab or steroids, clinicians should provide suitable patient information leaflets at discharge. Forms attached to this page can be used by clinicians with patients to support the discharge process. The materials have been developed in conjunction with Dhivya Subramaniam, NHS England and NHS Improvement. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 7, 2021 Category: Consumer Health News Source Type: news
Repurposing tocilizumab in scleroderma patients may prevent early lung disease
(Michigan Medicine - University of Michigan) A phase 3 clinical trial finds an anti-inflammatory drug used in rheumatoid arthritis can preserve lung function in patients with systemic sclerosis. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 31, 2021 Category: International Medicine & Public Health Source Type: news
Interleukin6 blocking agents for treating COVID19: a living systematic review, Cochrane Library
Authors ' conclusions On average, tocilizumab reduces all ‐cause mortality at D28 compared to standard care alone or placebo and probably results in slightly fewer serious adverse events than standard care alone or placebo. Nevertheless, tocilizumab probably results in little or no increase in the outcome clinical improvement (defined as hospital dischar ge or improvement measured by trialist‐defined scales) at D28. The impact of tocilizumab on other outcomes is uncertain or very uncertain. With the data available, we were not able to explore heterogeneity. Individual patient data meta‐analyses are needed to be able ...
Source: Current Awareness Service for Health (CASH) - March 25, 2021 Category: Consumer Health News Source Type: news
Can medicines that block interleukin-6 (a protein involved in immune responses) treat COVID-19?
This recently published Cochrane review examines the effects of a class of treatments on people with COVID-19. Treating COVID-19 with tocilizumab (a medicine that blocks interleukin-6) reduces the numbers of people who die within 28 days of treatment, and probably results in fewer serious unwanted effects than placebo treatment.Studies of other medicines that block interleukin-6 to treat COVID-19 are under way. The authors of this review will update this review when results from them become available.COVID-19COVID-19 is an infectious respiratory disease caused by a type of virus called a coronavirus. If the infection bec...
Source: Cochrane News and Events - March 18, 2021 Category: Information Technology Authors: Katie Abbotts Source Type: news
Roche Says Actemra-Remdesivir Trial Fails to Cut Hospital Stays Roche Says Actemra-Remdesivir Trial Fails to Cut Hospital Stays
Swiss drugmaker Roche said on Thursday adding its drug Actemra to Gilead Sciences ' Veklury medication, also called remdesivir, did not reduce hospital stays for patients with severe COVID-19 pneumonia.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - March 12, 2021 Category: Intensive Care Tags: Infectious Diseases News Source Type: news
Combo of Genentech, Gilead drugs fails Covid trial
The study is one of three late-stage clinical trials that Genentech has undertaken to assess the use of the rheumatoid arthritis drug Actemra in Covid patients with pneumonia. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 11, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news
Combo of Genentech, Gilead drugs fails Covid trial
The study is one of three late-stage clinical trials that Genentech has undertaken to assess the use of the rheumatoid arthritis drug Actemra in Covid patients with pneumonia. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 11, 2021 Category: American Health Authors: Ron Leuty Source Type: news
Tocilizumab Use Not Supported for Moderate-to-Severe COVID-19
THURSDAY, March 11, 2021 -- Tocilizumab is not associated with progression of COVID-19 among adults admitted to hospital with moderate-to-severe COVID-19, according to a study published online March 4 in The Lancet Respiratory Medicine.
Arvinder S.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 11, 2021 Category: Pharmaceuticals Source Type: news
Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia
Basel, 11 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the global phase III randomised, double-blind, multicentre REMDACTA study of Actemra ®/RoActemra® (tocilizumab) plus Veklury® (remdesivir), versus placebo plus Veklury, did not meet its primary endpoint. This was measured by improved time to hospital discharge up to day 28 in patients with severe COVID-19 pneumonia receiving standard of care. No new safety signals were identified for Actemra/RoActemra in the REMDACTA trial. The study was conducted in collaboration with Gilead Sciences, Inc. (Source: Roche Investor Update)
Source: Roche Investor Update - March 11, 2021 Category: Pharmaceuticals Source Type: news
Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia
Basel, 11 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the global phase III randomised, double-blind, multicentre REMDACTA study of Actemra ®/RoActemra® (tocilizumab) plus Veklury® (remdesivir), versus placebo plus Veklury, did not meet its primary endpoint. This was measured by improved time to hospital discharge up to day 28 in patients with severe COVID-19 pneumonia receiving standard of care. No new safety signals were identified for Actemra/RoActemra in the REMDACTA trial. The study was conducted in collaboration with Gilead Sciences, Inc. (Source: Roche Media News)
Source: Roche Media News - March 11, 2021 Category: Pharmaceuticals Source Type: news
Tocilizumab Scores FDA Approval for SSc-ILD Tocilizumab Scores FDA Approval for SSc-ILD
Tocilizumab is the first biologic to be approved by the agency for adults with systemic sclerosis –associated interstitial lung disease, a rare, potentially life-threatening condition.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 8, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news
Tocilizumab cuts mortality risk in severely ill COVID-19 patients finds new trial conducted in India
Tocilizumab, an anti-inflammatory drug used to treat rheumatoid arthritis, improves outcomes in severely ill COVID-19 patients, finds the results of a new trial conducted in hospitals across India — one of the world ’ s most ethnically diverse countries. (Source: University of Bristol news)
Source: University of Bristol news - March 8, 2021 Category: Universities & Medical Training Tags: Health, International, Publications, Research; Faculty of Health Sciences, Bristol Medical School; Press Release Source Type: news
Tocilizumab cuts mortality risk in severely ill COVID-19 patients finds new trial conducted in India
(University of Bristol) Tocilizumab, an anti-inflammatory drug used to treat rheumatoid arthritis, improves outcomes in severely ill COVID-19 patients, finds the results of a new trial conducted in hospitals across India -- one of the world's most ethnically diverse countries. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 8, 2021 Category: International Medicine & Public Health Source Type: news
